Jasso-Gutiérrez L, Ovando-Hernández JR, Castellanos-Solís EC, Escorza-Peña J, Santos-Preciado JI

Language: Spanish
References: 18
Page: 51-59
PDF size: 304.79 Kb.

ABSTRACT

Introduction. The development of a program of medical drug surveillance (PROFAVI) with online electronic capture in the Children Hospital of Mexico Federico Gomez (HIMFG) is described. It includes from its design up to the implementation as well as its potencialities and benefits.
Methods. A computer program was designed in Acces and Visual Basic, according to the Oficial Mexican Regulation (NOM), it included 5 stages (from design to liberation).
Results. Seven modules of data capture were made for: patient data, adverse reaction; suspected medication; other medication; clinical history; source of the information and statistical reports. Software and hardware requirements were: Explorer 5.0; Windows 98; free disc space de 5 GB; Acrobat Reader 5.0 and Excel 4.0; Pentium II + 500 Mhz; RAM 128 Mb; 1 024 x 768 píxeles y 16 bits monitor.
Conclusions. Advantages of PROFAVI: provide more reliability to the information and reduce capturing time; fullfill the NOM’s requirements, including attached data; establish a reference center at HIMFG, for the National Institutes of Health, State and Federal Hospitals; serve as a support element for research and education; increase the reporting culture in Mexico among other effects.

REFERENCES

1. Rodríguez-Betancourt JL, García-Vigil JL, Giral-Barnes C, Hernández-Santillán D, Jasso-Gutiérrez L. Farmacovigilancia I. El Inicio. Rev Med IMSS. 2004; 42: 327-9.

2. Jasso-Gutiérrez L, Castellanos-Solís EC, Santos-Preciado JI. Importancia de la Farmacovigilancia en Pediatría. Bol Med Hosp Infant Mex. 2009 (En prensa).

3. U.S. Food and Drug Administration. How to report problems with products regulated by FDA. http://www.fda.gov/opacom/backgrounders/problem.html (Consultado abril 23, 2008).

4. Health Canada. Drugs & Health Products. Reporting Adverse Reactions. https://www6.hc-sc.gc.ca/medeffect/disclaim.do (Consultado en 23 abril, 2008).

5. MHRA. Yellow Card. Reporting to the Yellow Card Scheme. https://yellowcard.mhra.gov.uk/mop/ (Consultado en abril 23, 2008).

6. Norma Oficial Mexicana NOM-220-SSA1-2002. Instalación y operación de la farmacovigilancia. D.O.F. Lunes 15 de noviembre del 2004. http://www.salud.gob.mx/unidades/cdi/nom/220ssa102.html (Consultado en febrero 28, 2008).

7. Secretaría de Salud. Dirección General de Insumos. SSA-03-021. Informe de sospechas de reacciones adversas a los medicamentos: http://www.probiomed.com.mx/farmacovigilancia/SECRETARIA_DE_SALUD.pdf (Consultado en abril 25, 2008).

8. Instituto Mexicano del Seguro Social. División Institucional de Cuadros Básicos. Centro Institucional de Farmacovigilancia. http://www.imss.gob.mx/cuadrosbasicos/farmaco%2Dvigilancia/ (Consultado en mayo 23, 2008).

9. Derbez-del Pino M, Márquez-Enríquez LM, García-Cruz MA, Ovando-Hernández R, Hernández-Santillán D, Jasso-Gutiérrez L. Sistema Institucional de Farmacovigilancia. Version 1. Dirección de Innovación y Desarrollo Tecnológico y División Institucional de Cuadros Básicos del Instituto Mexicano del Seguro Social. Última actualización 31 de agosto de 2006.

10. Kataoka S, Ohe K, Mochizuki M, Ueda S. Developing and integrating an adverse drug reaction reporting system with the hospital information system. Yakugaku Zasshi. 2002; 122: 113-6.

11. Hennig R. Electronic Reporting for Clinical Drug Safety and Pharmacovigilance. 29-30 October 2002, Amsterdam, The Netherlands. Expert Opin Drug Saf. 2003; 2: 195-7.

12. Almenoff JS. Innovations for the future of pharmacovigilance. Drug Saf. 2007; 30: 631-3.

13. The FDA Safety Information and Adverse Event Reporting Program. Med Watch Online Voluntary Reporting Form (3 500) https://www.accessdata.fda.gov/scripts/medwatch/ (Consultado en abril 23, 2008).

14. Ashcroft DM, Cooke J. Retrospective analysis of medication incidents reported using an on-line reporting system. Pharm World Sci. 2006; 28: 359-65.

15. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. Br J Clin Pharmacol. 2006; 63: 148-56.

16. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007; 25: 5374-80.

17. Kling A, Mjörndal T, Rantapää-Dahlqvist S. Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNF-alpha antagonists. J Clin Rheumatol. 2004; 10: 119-22.

18. Savage SW, Schneider PJ, Pedersen CA. Utility of an online medication-error-reporting system. Am J Health Syst Pharm. 2005; 62: 2265-70.